English
简体中文
Total: £ 56.28
Published Date: 2026-03-12 | Pages: 121 | Tables: 140 | Medical Care
The global Cell and Gene Therapy CDMO market was valued at US$ 4060 million in 2025 and is anticipated to reach US$ 6481 million by 2032, at a CAGR of 6.9% from 2026 to 2032.
Cell and Gene Therapy CDMOs are organizations that provide professional, customized R&D and manufacturing outsourcing services for the research and commercialization of cell and gene therapy drugs. These services cover the entire chain of process development and manufacturing, from plasmids and viral vectors to cell drugs. Their core value lies in helping innovative cell and gene therapy (CGT) companies overcome industrialization bottlenecks caused by complex processes, high production costs, and stringent regulatory oversight, accelerating the drug development process from preclinical research to IND application and commercialization. Services include process development, analytical method development, GMP-level manufacturing, stability studies, and application document preparation, making them an indispensable key support force in modern CGT drug development.
The global Cell and Gene Therapy CDMO market is experiencing rapid growth driven by the surge in CGT drugs, pipeline advancements, and industrialization demands. North America and Europe, as mature markets, leverage their leading viral vector technologies, robust regulatory frameworks, and extensive CGT R&D pipelines to hold leading positions in AAV suspension processes, lentiviral GMP production, and plasmid CDMO. The Asia-Pacific region has become the fastest-growing and most rapidly expanding sector. China, with its leading global number of cell therapy clinical studies, policy support, and CXO industry chain advantages, is driving the rapid rise of autologous CAR-T CDMO, universal cell therapy, and viral vector outsourcing services, with domestic CDMOs quickly entering global competition. The industry as a whole is accelerating its evolution towards suspension process scale-up, gene editing integration, and automated closed-loop production.
This report delivers a comprehensive overview of the global Cell and Gene Therapy CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cell and Gene Therapy CDMO. The Cell and Gene Therapy CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Cell and Gene Therapy CDMO market comprehensively. Regional market sizes by Type, by Application, by Scale, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Cell and Gene Therapy CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Lonza
Charles River Laboratories
Cytiva
Catalent Biologics
FUJIFILM Diosynth Biotechnologies
Made Scientific
RoslinCT
Thermo Scientific
Andelyn Biosciences
WuXi AppTec
AGC Biologics
Pfizer CentreOne
Almac Group
PCI Pharma Services
OmniaBio
Minaris Advanced Therapies
Segment by Type
Clinical Trial Material CDMOs
Development and Manufacturing CDMOs
Other
Segment by Scale
R&D-Grade CDMO
Clinical-Grade CDMO
Commercial-Scale CDMO
Segment by Technology
Plasmid DNA CDMO
Viral Vector CDMO
Cell Therapy CDMO
mRNA Drug CDMO
Gene Editing Drug CDMO
Others
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Scale, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Cell and Gene Therapy CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell and Gene Therapy CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Clinical Trial Material CDMOs
1.2.3 Development and Manufacturing CDMOs
1.2.4 Other
1.3 Market by Scale
1.3.1 Global Cell and Gene Therapy CDMO Market Size Growth Rate by Scale: 2021 vs 2025 vs 2032
1.3.2 R&D-Grade CDMO
1.3.3 Clinical-Grade CDMO
1.3.4 Commercial-Scale CDMO
1.4 Market by Technology
1.4.1 Global Cell and Gene Therapy CDMO Market Size Growth Rate by Technology: 2021 vs 2025 vs 2032
1.4.2 Plasmid DNA CDMO
1.4.3 Viral Vector CDMO
1.4.4 Cell Therapy CDMO
1.4.5 mRNA Drug CDMO
1.4.6 Gene Editing Drug CDMO
1.4.7 Others
1.5 Market by Application
1.5.1 Global Cell and Gene Therapy CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical Company
1.5.3 Biotechnology Company
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Cell and Gene Therapy CDMO Market Perspective (2021–2032)
2.2 Global Cell and Gene Therapy CDMO Growth Trends by Region
2.2.1 Global Cell and Gene Therapy CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Cell and Gene Therapy CDMO Historic Market Size by Region (2021–2026)
2.2.3 Cell and Gene Therapy CDMO Forecasted Market Size by Region (2027–2032)
2.3 Cell and Gene Therapy CDMO Market Dynamics
2.3.1 Cell and Gene Therapy CDMO Industry Trends
2.3.2 Cell and Gene Therapy CDMO Market Drivers
2.3.3 Cell and Gene Therapy CDMO Market Challenges
2.3.4 Cell and Gene Therapy CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell and Gene Therapy CDMO Players by Revenue
3.1.1 Global Top Cell and Gene Therapy CDMO Players by Revenue (2021–2026)
3.1.2 Global Cell and Gene Therapy CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Cell and Gene Therapy CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Cell and Gene Therapy CDMO Revenue
3.4 Global Cell and Gene Therapy CDMO Market Concentration Ratio
3.4.1 Global Cell and Gene Therapy CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell and Gene Therapy CDMO Revenue in 2025
3.5 Global Key Players of Cell and Gene Therapy CDMO Head Offices and Areas Served
3.6 Global Key Players of Cell and Gene Therapy CDMO, Products and Applications
3.7 Global Key Players of Cell and Gene Therapy CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Cell and Gene Therapy CDMO Breakdown Data by Type
4.1 Global Cell and Gene Therapy CDMO Historic Market Size by Type (2021–2026)
4.2 Global Cell and Gene Therapy CDMO Forecasted Market Size by Type (2027–2032)
5 Cell and Gene Therapy CDMO Breakdown Data by Application
5.1 Global Cell and Gene Therapy CDMO Historic Market Size by Application (2021–2026)
5.2 Global Cell and Gene Therapy CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Cell and Gene Therapy CDMO Market Size (2021–2032)
6.2 North America Cell and Gene Therapy CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Cell and Gene Therapy CDMO Market Size by Country (2021–2026)
6.4 North America Cell and Gene Therapy CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cell and Gene Therapy CDMO Market Size (2021–2032)
7.2 Europe Cell and Gene Therapy CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Cell and Gene Therapy CDMO Market Size by Country (2021–2026)
7.4 Europe Cell and Gene Therapy CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Cell and Gene Therapy CDMO Market Size (2021–2032)
8.2 Asia-Pacific Cell and Gene Therapy CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Cell and Gene Therapy CDMO Market Size (2021–2032)
9.2 Latin America Cell and Gene Therapy CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Cell and Gene Therapy CDMO Market Size by Country (2021–2026)
9.4 Latin America Cell and Gene Therapy CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell and Gene Therapy CDMO Market Size (2021–2032)
10.2 Middle East & Africa Cell and Gene Therapy CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Cell and Gene Therapy CDMO Introduction
11.1.4 Lonza Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.1.5 Lonza Recent Development
11.2 Charles River Laboratories
11.2.1 Charles River Laboratories Company Details
11.2.2 Charles River Laboratories Business Overview
11.2.3 Charles River Laboratories Cell and Gene Therapy CDMO Introduction
11.2.4 Charles River Laboratories Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.2.5 Charles River Laboratories Recent Development
11.3 Cytiva
11.3.1 Cytiva Company Details
11.3.2 Cytiva Business Overview
11.3.3 Cytiva Cell and Gene Therapy CDMO Introduction
11.3.4 Cytiva Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.3.5 Cytiva Recent Development
11.4 Catalent Biologics
11.4.1 Catalent Biologics Company Details
11.4.2 Catalent Biologics Business Overview
11.4.3 Catalent Biologics Cell and Gene Therapy CDMO Introduction
11.4.4 Catalent Biologics Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.4.5 Catalent Biologics Recent Development
11.5 FUJIFILM Diosynth Biotechnologies
11.5.1 FUJIFILM Diosynth Biotechnologies Company Details
11.5.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.5.3 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Introduction
11.5.4 FUJIFILM Diosynth Biotechnologies Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.5.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.6 Made Scientific
11.6.1 Made Scientific Company Details
11.6.2 Made Scientific Business Overview
11.6.3 Made Scientific Cell and Gene Therapy CDMO Introduction
11.6.4 Made Scientific Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.6.5 Made Scientific Recent Development
11.7 RoslinCT
11.7.1 RoslinCT Company Details
11.7.2 RoslinCT Business Overview
11.7.3 RoslinCT Cell and Gene Therapy CDMO Introduction
11.7.4 RoslinCT Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.7.5 RoslinCT Recent Development
11.8 Thermo Scientific
11.8.1 Thermo Scientific Company Details
11.8.2 Thermo Scientific Business Overview
11.8.3 Thermo Scientific Cell and Gene Therapy CDMO Introduction
11.8.4 Thermo Scientific Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.8.5 Thermo Scientific Recent Development
11.9 Andelyn Biosciences
11.9.1 Andelyn Biosciences Company Details
11.9.2 Andelyn Biosciences Business Overview
11.9.3 Andelyn Biosciences Cell and Gene Therapy CDMO Introduction
11.9.4 Andelyn Biosciences Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.9.5 Andelyn Biosciences Recent Development
11.10 WuXi AppTec
11.10.1 WuXi AppTec Company Details
11.10.2 WuXi AppTec Business Overview
11.10.3 WuXi AppTec Cell and Gene Therapy CDMO Introduction
11.10.4 WuXi AppTec Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.10.5 WuXi AppTec Recent Development
11.11 AGC Biologics
11.11.1 AGC Biologics Company Details
11.11.2 AGC Biologics Business Overview
11.11.3 AGC Biologics Cell and Gene Therapy CDMO Introduction
11.11.4 AGC Biologics Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.11.5 AGC Biologics Recent Development
11.12 Pfizer CentreOne
11.12.1 Pfizer CentreOne Company Details
11.12.2 Pfizer CentreOne Business Overview
11.12.3 Pfizer CentreOne Cell and Gene Therapy CDMO Introduction
11.12.4 Pfizer CentreOne Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.12.5 Pfizer CentreOne Recent Development
11.13 Almac Group
11.13.1 Almac Group Company Details
11.13.2 Almac Group Business Overview
11.13.3 Almac Group Cell and Gene Therapy CDMO Introduction
11.13.4 Almac Group Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.13.5 Almac Group Recent Development
11.14 PCI Pharma Services
11.14.1 PCI Pharma Services Company Details
11.14.2 PCI Pharma Services Business Overview
11.14.3 PCI Pharma Services Cell and Gene Therapy CDMO Introduction
11.14.4 PCI Pharma Services Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.14.5 PCI Pharma Services Recent Development
11.15 OmniaBio
11.15.1 OmniaBio Company Details
11.15.2 OmniaBio Business Overview
11.15.3 OmniaBio Cell and Gene Therapy CDMO Introduction
11.15.4 OmniaBio Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.15.5 OmniaBio Recent Development
11.16 Minaris Advanced Therapies
11.16.1 Minaris Advanced Therapies Company Details
11.16.2 Minaris Advanced Therapies Business Overview
11.16.3 Minaris Advanced Therapies Cell and Gene Therapy CDMO Introduction
11.16.4 Minaris Advanced Therapies Revenue in Cell and Gene Therapy CDMO Business (2021–2026)
11.16.5 Minaris Advanced Therapies Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Cell and Gene Therapy CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Clinical Trial Material CDMOs
Table 3. Key Players of Development and Manufacturing CDMOs
Table 4. Key Players of Other
Table 5. Global Cell and Gene Therapy CDMO Market Size Growth Rate by Scale (US$ Million): 2021 vs 2025 vs 2032
Table 6. Key Players of R&D-Grade CDMO
Table 7. Key Players of Clinical-Grade CDMO
Table 8. Key Players of Commercial-Scale CDMO
Table 9. Global Cell and Gene Therapy CDMO Market Size Growth Rate by Technology (US$ Million): 2021 vs 2025 vs 2032
Table 10. Key Players of Plasmid DNA CDMO
Table 11. Key Players of Viral Vector CDMO
Table 12. Key Players of Cell Therapy CDMO
Table 13. Key Players of mRNA Drug CDMO
Table 14. Key Players of Gene Editing Drug CDMO
Table 15. Key Players of Others
Table 16. Global Cell and Gene Therapy CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Cell and Gene Therapy CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 18. Global Cell and Gene Therapy CDMO Market Size by Region (US$ Million), 2021–2026
Table 19. Global Cell and Gene Therapy CDMO Market Share by Region (2021–2026)
Table 20. Global Cell and Gene Therapy CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
Table 21. Global Cell and Gene Therapy CDMO Market Share by Region (2027–2032)
Table 22. Cell and Gene Therapy CDMO Market Trends
Table 23. Cell and Gene Therapy CDMO Market Drivers
Table 24. Cell and Gene Therapy CDMO Market Challenges
Table 25. Cell and Gene Therapy CDMO Market Restraints
Table 26. Global Cell and Gene Therapy CDMO Revenue by Players (US$ Million), 2021–2026
Table 27. Global Cell and Gene Therapy CDMO Market Share by Players (2021–2026)
Table 28. Global Top Cell and Gene Therapy CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Cell and Gene Therapy CDMO Revenue, 2025
Table 29. Ranking of Global Top Cell and Gene Therapy CDMO Companies by Revenue (US$ Million) in 2025
Table 30. Global 5 Largest Players Market Share by Cell and Gene Therapy CDMO Revenue (CR5 and HHI), 2021–2026
Table 31. Global Key Players of Cell and Gene Therapy CDMO, Headquarters and Area Served
Table 32. Global Key Players of Cell and Gene Therapy CDMO, Products and Applications
Table 33. Global Key Players of Cell and Gene Therapy CDMO, Date of General Availability (GA)
Table 34. Mergers and Acquisitions, Expansion Plans
Table 35. Global Cell and Gene Therapy CDMO Market Size by Type (US$ Million), 2021–2026
Table 36. Global Cell and Gene Therapy CDMO Revenue Market Share by Type (2021–2026)
Table 37. Global Cell and Gene Therapy CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
Table 38. Global Cell and Gene Therapy CDMO Revenue Market Share by Type (2027–2032)
Table 39. Global Cell and Gene Therapy CDMO Market Size by Application (US$ Million), 2021–2026
Table 40. Global Cell and Gene Therapy CDMO Revenue Market Share by Application (2021–2026)
Table 41. Global Cell and Gene Therapy CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
Table 42. Global Cell and Gene Therapy CDMO Revenue Market Share by Application (2027–2032)
Table 43. North America Cell and Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. North America Cell and Gene Therapy CDMO Market Size by Country (US$ Million), 2021–2026
Table 45. North America Cell and Gene Therapy CDMO Market Size by Country (US$ Million), 2027–2032
Table 46. Europe Cell and Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 47. Europe Cell and Gene Therapy CDMO Market Size by Country (US$ Million), 2021–2026
Table 48. Europe Cell and Gene Therapy CDMO Market Size by Country (US$ Million), 2027–2032
Table 49. Asia-Pacific Cell and Gene Therapy CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 50. Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region (US$ Million), 2021–2026
Table 51. Asia-Pacific Cell and Gene Therapy CDMO Market Size by Region (US$ Million), 2027–2032
Table 52. Latin America Cell and Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 53. Latin America Cell and Gene Therapy CDMO Market Size by Country (US$ Million), 2021–2026
Table 54. Latin America Cell and Gene Therapy CDMO Market Size by Country (US$ Million), 2027–2032
Table 55. Middle East & Africa Cell and Gene Therapy CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 56. Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country (US$ Million), 2021–2026
Table 57. Middle East & Africa Cell and Gene Therapy CDMO Market Size by Country (US$ Million), 2027–2032
Table 58. Lonza Company Details
Table 59. Lonza Business Overview
Table 60. Lonza Cell and Gene Therapy CDMO Product
Table 61. Lonza Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 62. Lonza Recent Development
Table 63. Charles River Laboratories Company Details
Table 64. Charles River Laboratories Business Overview
Table 65. Charles River Laboratories Cell and Gene Therapy CDMO Product
Table 66. Charles River Laboratories Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 67. Charles River Laboratories Recent Development
Table 68. Cytiva Company Details
Table 69. Cytiva Business Overview
Table 70. Cytiva Cell and Gene Therapy CDMO Product
Table 71. Cytiva Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 72. Cytiva Recent Development
Table 73. Catalent Biologics Company Details
Table 74. Catalent Biologics Business Overview
Table 75. Catalent Biologics Cell and Gene Therapy CDMO Product
Table 76. Catalent Biologics Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 77. Catalent Biologics Recent Development
Table 78. FUJIFILM Diosynth Biotechnologies Company Details
Table 79. FUJIFILM Diosynth Biotechnologies Business Overview
Table 80. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product
Table 81. FUJIFILM Diosynth Biotechnologies Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 82. FUJIFILM Diosynth Biotechnologies Recent Development
Table 83. Made Scientific Company Details
Table 84. Made Scientific Business Overview
Table 85. Made Scientific Cell and Gene Therapy CDMO Product
Table 86. Made Scientific Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 87. Made Scientific Recent Development
Table 88. RoslinCT Company Details
Table 89. RoslinCT Business Overview
Table 90. RoslinCT Cell and Gene Therapy CDMO Product
Table 91. RoslinCT Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 92. RoslinCT Recent Development
Table 93. Thermo Scientific Company Details
Table 94. Thermo Scientific Business Overview
Table 95. Thermo Scientific Cell and Gene Therapy CDMO Product
Table 96. Thermo Scientific Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 97. Thermo Scientific Recent Development
Table 98. Andelyn Biosciences Company Details
Table 99. Andelyn Biosciences Business Overview
Table 100. Andelyn Biosciences Cell and Gene Therapy CDMO Product
Table 101. Andelyn Biosciences Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 102. Andelyn Biosciences Recent Development
Table 103. WuXi AppTec Company Details
Table 104. WuXi AppTec Business Overview
Table 105. WuXi AppTec Cell and Gene Therapy CDMO Product
Table 106. WuXi AppTec Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 107. WuXi AppTec Recent Development
Table 108. AGC Biologics Company Details
Table 109. AGC Biologics Business Overview
Table 110. AGC Biologics Cell and Gene Therapy CDMO Product
Table 111. AGC Biologics Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 112. AGC Biologics Recent Development
Table 113. Pfizer CentreOne Company Details
Table 114. Pfizer CentreOne Business Overview
Table 115. Pfizer CentreOne Cell and Gene Therapy CDMO Product
Table 116. Pfizer CentreOne Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 117. Pfizer CentreOne Recent Development
Table 118. Almac Group Company Details
Table 119. Almac Group Business Overview
Table 120. Almac Group Cell and Gene Therapy CDMO Product
Table 121. Almac Group Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 122. Almac Group Recent Development
Table 123. PCI Pharma Services Company Details
Table 124. PCI Pharma Services Business Overview
Table 125. PCI Pharma Services Cell and Gene Therapy CDMO Product
Table 126. PCI Pharma Services Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 127. PCI Pharma Services Recent Development
Table 128. OmniaBio Company Details
Table 129. OmniaBio Business Overview
Table 130. OmniaBio Cell and Gene Therapy CDMO Product
Table 131. OmniaBio Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 132. OmniaBio Recent Development
Table 133. Minaris Advanced Therapies Company Details
Table 134. Minaris Advanced Therapies Business Overview
Table 135. Minaris Advanced Therapies Cell and Gene Therapy CDMO Product
Table 136. Minaris Advanced Therapies Revenue in Cell and Gene Therapy CDMO Business (US$ Million), 2021–2026
Table 137. Minaris Advanced Therapies Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
Table 141. Authors List of This Report
List of Figures
Figure 1. Cell and Gene Therapy CDMO Picture
Figure 2. Global Cell and Gene Therapy CDMO Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Cell and Gene Therapy CDMO Market Share by Type: 2025 vs 2032
Figure 4. Clinical Trial Material CDMOs Features
Figure 5. Development and Manufacturing CDMOs Features
Figure 6. Other Features
Figure 7. Global Cell and Gene Therapy CDMO Market Size Comparison by Scale (US$ Million), 2021–2032
Figure 8. R&D-Grade CDMO Features
Figure 9. Clinical-Grade CDMO Features
Figure 10. Commercial-Scale CDMO Features
Figure 11. Global Cell and Gene Therapy CDMO Market Size Comparison by Technology (US$ Million), 2021–2032
Figure 12. Plasmid DNA CDMO Features
Figure 13. Viral Vector CDMO Features
Figure 14. Cell Therapy CDMO Features
Figure 15. mRNA Drug CDMO Features
Figure 16. Gene Editing Drug CDMO Features
Figure 17. Others Features
Figure 18. Global Cell and Gene Therapy CDMO Market Size by Application (US$ Million), 2021–2032
Figure 19. Global Cell and Gene Therapy CDMO Market Share by Application: 2025 vs 2032
Figure 20. Pharmaceutical Company Case Studies
Figure 21. Biotechnology Company Case Studies
Figure 22. Other Case Studies
Figure 23. Cell and Gene Therapy CDMO Report Years Considered
Figure 24. Global Cell and Gene Therapy CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 25. Global Cell and Gene Therapy CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global Cell and Gene Therapy CDMO Market Share by Region: 2025 vs 2032
Figure 27. Global Cell and Gene Therapy CDMO Market Share by Players in 2025
Figure 28. Global Cell and Gene Therapy CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 29. The Top 10 and 5 Players Market Share by Cell and Gene Therapy CDMO Revenue in 2025
Figure 30. North America Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. North America Cell and Gene Therapy CDMO Market Share by Country (2021–2032)
Figure 32. United States Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Canada Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Europe Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Europe Cell and Gene Therapy CDMO Market Share by Country (2021–2032)
Figure 36. Germany Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. France Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. U.K. Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Italy Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Russia Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Ireland Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Asia-Pacific Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Asia-Pacific Cell and Gene Therapy CDMO Market Share by Region (2021–2032)
Figure 44. China Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Japan Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. South Korea Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Southeast Asia Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. India Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Australia & New Zealand Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Latin America Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Latin America Cell and Gene Therapy CDMO Market Share by Country (2021–2032)
Figure 52. Mexico Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Brazil Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 54. Middle East & Africa Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 55. Middle East & Africa Cell and Gene Therapy CDMO Market Share by Country (2021–2032)
Figure 56. Israel Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 57. Saudi Arabia Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 58. UAE Cell and Gene Therapy CDMO Market Size YoY Growth (US$ Million), 2021–2032
Figure 59. Lonza Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 60. Charles River Laboratories Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 61. Cytiva Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 62. Catalent Biologics Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 63. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 64. Made Scientific Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 65. RoslinCT Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 66. Thermo Scientific Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 67. Andelyn Biosciences Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 68. WuXi AppTec Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 69. AGC Biologics Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 70. Pfizer CentreOne Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 71. Almac Group Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 72. PCI Pharma Services Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 73. OmniaBio Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 74. Minaris Advanced Therapies Revenue Growth Rate in Cell and Gene Therapy CDMO Business (2021–2026)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
